UNSPSC 51111910: Paclitaxel poliglumex

This classification denotes a taxane compound and paclitaxel preparation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQ64FZ98ZN. European Medicines Agency schedules Paclitaxel poliglumex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27755.

Paclitaxel poliglumex generally arises in the molecular formula C10H16N2O7(C52H56N2O16)N(C5H7NO3)N. The term PACLITAXEL POLIGLUMEX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 3, 2004, list 52.) Most nations schedule paclitaxel poliglumex under HS 39089000 and SITC 57539. As of Q4 2014, PACLITAXEL POLIGLUMEX remains the US FDA Preferred Term for this commodity. Paclitaxel poliglumex bears US NLM identifiers UMLS ID C1702776 and NCI Concept Code C1795.

UNSPSC 51111910 Paclitaxel poliglumex is a Commodity code covering a specific chemotherapy agent used in cancer treatment. State and local health agencies and pharmacy benefit programs procure this drug through pharmacy contracts, disease-specific treatment protocols, and institutional purchasing agreements. The recent activity under this code reflects broader state efforts to optimize pharmaceutical procurement by establishing direct relationships with manufacturers and managing acquisition costs through alternative contracting models outside traditional pharmacy benefit manager and group purchasing organization arrangements.

The Texas Health and Human Services Commission posted Request for Information No. HHS0017013 on April 3, 2026, seeking vendor capabilities for its Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI solicited responses from vendors and stakeholders about implementing direct contracting between the state pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management. Vendors were asked to demonstrate experience with direct contracting for self-insured employers and health plans, flexibility to negotiate using net pricing models without rebates, and capability to support value-based or outcomes-based agreements. The RFI was exploratory in nature, designed to inform the state's future procurement strategy before issuing a formal RFP; no award values, budget ranges, or set-aside designations were specified at the information-gathering phase.